Fractyl Health Inc GUTS

$0.99 +0.10 (11.24%)

Valuation

Market cap
11,801,000
Revenue TTM
$0
Net income TTM
$-140,950,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
-18.23

Trading

Volume
710,800
Avg volume
565,239
Day's range
$0.86 – $1.02
Shares out
13,260,000
Stochastic %K
24%
Beta
2.42
Analysts
Strong Sell
Price target
$24.67

Price

Company profile

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated vi...

Show more

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
781 902 8800
Website
https://fractyl.com
Address
3 Van de Graaff Drive, Suite 200, Burlington, United States

Latest news

Stocktwits

topstockalerts Oct 29, 9:40 PM
$GUTS not much pullback at all… that’s interesting
0 replies
Valueforall Oct 29, 8:48 PM
$GUTS he’s active on the $IOVA and $SLS boards
1 replies
Valueforall Oct 29, 8:43 PM
$GUTS nice bounce today. High conviction play from @BioRich 👏 on his call to buy lower
1 replies
Valueforall Oct 29, 8:40 PM
$IOVA whats the latest on the $GUTS aftermath. Reducing average and buying lower? Or just focus on SLS
2 replies
biotechblackswan Oct 29, 8:22 PM
$GUTS “Rising healthcare costs and pharmaceutical spending, specifically on GLP-1 drugs, drove the biggest financial losses in the plan’s history.” This is what happened to blue cross blue shield Massachusetts. Similar situations with other plans. If revita can somehow reduce cost of healthcare plans it can be preferred route over glp 1s in some instances !!
1 replies
BrandoS Oct 29, 4:04 PM
$GUTS Bounce this over $1. I’m all in here for the dead cat
1 replies
Allergictobears Oct 29, 3:14 PM
$GUTS GOnna delist again? Lol need another R/S soon ...
0 replies
TraderBuckNKY Oct 29, 1:07 PM
$GUTS BURLINGTON, Mass. , Oct. 29, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl ), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced findings from company-sponsored market research highlighting strong patient interest in a one-time procedural approach to weight maintenance following GLP-1 therapy. The findings reinforce the commercial opportunity for investigational Revita. Fractyl estimates that approx. 1 million patients each month in the United States face the challenge of weight regain following discontinuation. 65% of those taking a GLP-1 for weight loss (without type 2 diabetes) stop within one year, and only about 1 in 12 people prescribed a GLP-1 for obesity are still on it after three years [1,2]. Revita is being developed to address this post-GLP-1 weight maintenance need.
0 replies